Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging for Glioblastoma (GBM)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Glioblastoma (GBM)+1 MoreDynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging - DiagnosticTest
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial uses DSC-MRI to measure rCBV to determine response to bevacizumab in patients with recurrent glioblastoma. DSC-MRI may help to evaluate changes in cancer blood vessels.

Eligible Conditions
  • Glioblastoma (GBM)
  • Gliosarcoma

Treatment Effectiveness

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: Up to 5 years

Baseline
CBF
rCBV
Baseline to 2 weeks
Change in CBF
Change in rCBV within enhancing tumor
Up to 5 years
OS
PFS

Trial Safety

Trial Design

1 Treatment Group

Diagnostic (DSC-MRI)
1 of 1

Experimental Treatment

146 Total Participants · 1 Treatment Group

Primary Treatment: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging · No Placebo Group · N/A

Diagnostic (DSC-MRI)
DiagnosticTest
Experimental Group · 1 Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging · Intervention Types: DiagnosticTest
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
2006
Completed Early Phase 1
~290

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years

Who is running the clinical trial?

ECOG-ACRIN Cancer Research GroupLead Sponsor
103 Previous Clinical Trials
171,889 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,071 Previous Clinical Trials
41,128,709 Total Patients Enrolled
Jerrold BoxermanPrincipal InvestigatorECOG-ACRIN Cancer Research Group

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The presence of a tumor in the setting of progressive enhancement on MRI is strongly associated with the development of tumor recurrence.
Patients who have a new recurrence of their disease within 3 months of treatment with bevacizumab, and have no contraindications to bevacizumab, are eligible for this trial.
You have not been treated previously with immunotherapies (vaccines, checkpoint inhibitors, T-cells).
Patients must be able to tolerate brain MRI scans with dynamic intravenous gadolinium-based contrast agent injections.
You have a histologically proven intracranial glioblastoma or gliosarcoma at initial surgery.
You have a Karnofsky performance status of 70 or higher.